- Indication
- Growth disturbance caused by growth hormone deficiency in children
- RAG rating
- Red
- Document type
- Decision document
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Somatrogon (Ngenla)
Somatrogon (Ngenla)
HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)
Somatrogon for treating growth disturbance in children and young people aged 3 years and over
RED
Recommended for restricted prescribing by specialist only.
Not recommended for primary care prescribing.
Name generic (trade) Somatrogon (Ngenla®)
What it is Recombinant human growth hormone
Indication Licensed for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
Date decision last revised March 2023
Decision status Interim*
NICE / SMC Guidance NICE TA 863 recommended, SMC accepted for use
HWE APC recommendation:
Somatrogon is recommended, within its marketing authorisation, as an option for treating growth disturbance in children and young people aged 3 years and over in line with the recommendations in NICE TA 863.
Somatrogon treatment should be reviewed in line with discontinuation criteria already agreed across HWE ICB for somatropin treatment:
Poor response: growth velocity in the first year of treatment <50% above baseline value
Growth velocity is less than <2cm total growth in 1 year
Final height is attained. Confirmation of final height: bone age is >14yrs (girls) or >16yrs (boys)
Insurmountable problems with adherence
National tariff excluded.
If somatrogon is considered one of a number of suitable treatments (including any preparation of somatropin),
the least expensive (taking into account administration costs, dosage, price per dose and commercial arrangements) should be chosen.
RED STATUS*:
NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING.
RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALISTS
* Prescribing RAG recommendation to be reviewed at a future HWE APC meeting following consultations with local specialists and tertiary centres
NICE TA 853 recommendations:
Somatrogon is recommended, within its marketing authorisation, as an option for treating growth disturbance caused by growth hormone deficiency in children and young people aged 3 years and over.
If people with the condition and their clinicians, consider somatrogon to be 1 of a range of suitable treatments (including any preparation of somatropin) discuss the advantages and disadvantages of the available treatments. After that discussion, if more than 1 treatment is suitable, choose the least expensive. Take account of administration costs, dosage, price per dose and commercial arrangements.